Skip to content
Dosage GuideResearch Reference

Vapreotide Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Vapreotide. All information is for educational purposes only.

Quick Answer

Vapreotide is typically administered intravenously for acute esophageal variceal bleeding. The standard regimen involves an initial bolus followed by a continuous infusion. Dosage may be adjusted based on patient response and liver function. Subcutaneous administration is also used in some cases for longer-term management of neuroendocrine tumors.

→ Vapreotide Benefits→ Vapreotide Side Effects→ Full Vapreotide Profile
Table of Contents

Standard Dosage Range

Research dosing range: Initial bolus of 25-50 mcg IV followed by continuous infusion of 25-50 mcg/hour

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Acute Esophageal Variceal Bleeding

25-50 mcg bolusOnce, then continuous infusion
Duration

Up to 5 days

Administered intravenously as an initial bolus followed by continuous infusion. Monitor for bleeding control and adjust infusion rate accordingly. Used in conjunction with endoscopic therapy.

Neuroendocrine Tumors (symptomatic relief)

50-300 mcg2-3 times daily
Duration

Ongoing, individualized

Administered subcutaneously. Dosage is highly individualized based on symptom control (e.g., diarrhea, flushing) and tumor type. Titrate to effect while monitoring for side effects.

Acromegaly (adjunct therapy)

100-300 mcg2-3 times daily
Duration

Ongoing, individualized

Administered subcutaneously. Used as an adjunct to surgery or radiation therapy, or as monotherapy in patients not suitable for other treatments. Monitor growth hormone and IGF-1 levels.

Timing & Frequency

For acute variceal bleeding, vapreotide is initiated immediately upon diagnosis. For neuroendocrine tumors and acromegaly, subcutaneous injections are typically administered before meals to maximize symptom control.

Cycle Guidance

For acute variceal bleeding, vapreotide is used for a short duration (typically up to 5 days). For chronic conditions like neuroendocrine tumors or acromegaly, vapreotide may be used long-term under medical supervision. Regular monitoring for side effects is essential.

Reconstitution Reference

Quick reference for reconstituting Vapreotide. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 0.5 mg per vial
BAC Water VolumeRefer to product insert for reconstitution instructions based on desired concentration
Concentration & DrawConcentration varies depending on reconstitution volume; refer to product insert
StorageRefrigerate reconstituted solution as per product insert. Store lyophilized powder as per manufacturer instructions.
StabilityRefer to product insert for stability information of reconstituted solution and lyophilized powder.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard dose for esophageal variceal bleeding?
The typical regimen involves an initial IV bolus of 25-50 mcg, followed by a continuous IV infusion of 25-50 mcg/hour for up to 5 days, in conjunction with endoscopic therapy.
How is vapreotide administered for neuroendocrine tumors?
Vapreotide is administered subcutaneously for neuroendocrine tumors, typically 2-3 times daily. The dose is individualized based on symptom control and tolerance.
What are the potential side effects of vapreotide?
Common side effects include abdominal pain, nausea, vomiting, and injection site reactions. Serious side effects may include bradycardia, cardiac conduction changes, and gallbladder problems. Hyperglycemia or hypoglycemia can also occur.

Last updated: 2026-02-19